alzheimer's semaglutide does not slow the progression of disease Novo Nordisk's oral GLP-1 drug

In addition, the FDA maintains a system of postmarketing surveillance and risk assessment programs to identify and evaluate adverse events that did not appear during the drug development process

We serve patients from Buckeye AZ, Liberty AZ, Westpark AZ, Goodyear AZ, Glendale AZ, and surrounding areas

Deaths in semaglutide FAERS reports since 2020 (USA TODAY/Gannett analysis) Pending cases in GLP-1 MDL-3094 up 153% in 14 months (MDL Update) Americans currently using a GLP-1 drug (KFF Health Tracking Poll) What the FDA Found The warning letter details five specific cases where Novo Nordisk's internal procedures prevented adverse events from reaching the FDA

Exposure to temperatures above 86F (30C) can degrade the medication rapidly, rendering it unusable